HCMC – The National Committee for Ethics in Biomedicine Research on September 18 adopted the mid-term assessment report of the third phase of clinical trials of the domestically developed Covid-19 vaccine Nano Covax.
In the report, the HCMC-based Nanogen Pharmaceutical Biotechnology JSC, developer of Nano Covax, updated information about the vaccine’s immunogenicity on the most common coronavirus strains including the Delta (first detected in India) and Alpha (first detected in the UK) strains.
Members of the committee also approved data about the vaccine’s safety and protection efficacy.
Within three days after the National Committee for Ethics in Biomedicine Research passed the report, the Advisory Council for the Registration of Circulation of Drugs and Medicinal Ingredients will review the report.
The council would whether submit it to the Ministry of Health for approval or ask Nanogen to provide more data if necessary.
This is the second time that the National Committee for Ethics in Biomedicine Research has adopted the mid-term assessment report of the third phase of clinical trials of Nano Covax. However, some experts said the latest report contains more data compared with the previous one.
Nanogen has also sent data about the clinical trials of Nano Covax to the World Health Organization (WHO) and attended WHO’s meeting on the vaccine’s protection efficacy.
Nano Covax, a recombinant spike protein vaccine, is the frontrunner among Vietnamese-made Covid-19 vaccine candidates. To date it is the only home-grown Covid-19 vaccine candidate that has entered the third phase of clinical trials.
